Imatinib, better known as Gleevec, was hailed as a "miracle" cancer drug when it entered the market in the early 2000s. Though it has been highly successful at treating early-stage chronic myeloid leukemia (CML)—a rare ...
Jun 1, 2022
0
150
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS), and increasingly in other diseases, but their mechanism of action is not clear. HMAs may affect many ...
May 26, 2022
0
18
The body's innate immune system, active from birth, is the first line of defense against viruses and other pathogens that cause disease. Using vaccination as an example, after receiving a vaccine, pain, redness, or swelling ...
May 25, 2022
0
179
A group of researchers at Children's Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an "off-the-shelf" chimeric antigen receptor T-cell (CART) using base editing, which ...
May 23, 2022
0
25
The long-term survival of adolescent and young adult (AYA) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) survivors was shorter than that of the general population, and the differences persisted for up ...
May 13, 2022
0
5
Hormone therapy is often used to treat prostate cancer that has spread to other parts of the body, but many patients develop resistance to hormone therapy, causing their disease to become more aggressive and potentially more ...
May 10, 2022
0
34
By using new methods for analyzing DNA data and medical records, researchers from Brown University are helping improve the understanding of complex traits that will make more discoveries relevant to non-white, non-European ...
May 4, 2022
0
18
Massachusetts General Hospital (MGH) researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute ...
Apr 28, 2022
0
5
Cancer researchers at the University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, and at the Medical Faculty of Kiel University have described approaches for improved therapy of adult blood cancer patients in a ...
Apr 21, 2022
0
28
Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction chemotherapy, ...
Apr 21, 2022
0
13
